Core Viewpoint - The company *ST Shuangcheng has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for injectable bortezomib, indicating that the product is bioequivalent and therapeutically equivalent to the reference drug [1] Group 1: FDA Approval - The U.S. FDA has completed a comprehensive technical review of the ANDA submitted by the company [1] - The approval confirms that the company's product is equivalent in terms of biological and therapeutic effects to the original drug [1] Group 2: Approved Indications - The approved indications for the injectable bortezomib include: 1. Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] 2. Part of a combination therapy for previously untreated multiple myeloma patients under 65 years old, used for high-dose chemotherapy with autologous stem cell rescue following prior induction therapy [1] 3. Treatment for multiple myeloma patients who have received at least one prior therapy and whose disease has progressed [1] 4. Treatment of adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]

Market Performance - The Hainan Free Trade Zone concept declined by 3.33%, ranking among the top declines in concept sectors, with New Dazhou A hitting the limit down, and Kangzhi Pharmaceutical, Hainan Haiyao, and Xinlong Holdings also experiencing significant declines [1] - Among the stocks in the Hainan Free Trade Zone concept, only four stocks saw price increases, with Zhongtung High-tech, Hainan Development, and *ST Yedao rising by 2.86%, 2.41%, and 1.56% respectively [1] Capital Flow - The Hainan Free Trade Zone concept experienced a net outflow of 1.318 billion yuan, with 26 stocks seeing net outflows, and 12 stocks having net outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Haima Automobile, with a net outflow of 185 million yuan, followed by Hainan Haiyao and Shennong Seed Industry with net outflows of 184 million yuan and 146 million yuan respectively [2] - Stocks with the highest net inflows included Zhongtung High-tech, *ST Yedao, and *ST Shuangcheng, with net inflows of 122 million yuan, 1.288 million yuan, and 1.159 million yuan respectively [2] Stock Performance - The top decliners in the Hainan Free Trade Zone concept included Haima Automobile (-6.09%), Hainan Haiyao (-7.67%), and Shennong Seed Industry (-6.83%) [3] - The stock with the highest turnover rate was Haima Automobile at 14.27%, while Hainan Haiyao had a turnover rate of 17.29% [3] - Stocks like Zhongtung High-tech and *ST Yedao showed positive performance with increases of 2.86% and 1.56% respectively, despite the overall decline in the sector [3]

北京市中伦律师事务所 关于海南双成药业股份有限公司 北京市中伦律师事务所 关于海南双成药业股份有限公司 2025 年第三次临时股东会的 法律意见书 二〇二五年十二月 2025 年第三次临时股东会的 法律意见书 致：海南双成药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受海南双成药业股份有限公 司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》《上市公司股东会规则》（以下简称《股东会 规则》）等法律、法规、规范性文件及《海南双成药业股份有限公司章程》（以下 简称《公司章程》）的有关规定，就公司 2025 年第三次临时股东会（以下简称"本 次股东会"）有关事宜出具本法律意见书。 本法律意见书仅就本次股东会的召集人资格、召集和召开程序、出席本次股 东会人员的资格（但不包含网络投票股东的资格）、会议表决程序是否符合法律、 法规、规范性文件及《公司章程》的规定以及表决结果是否合法有效发表意见， 而不对本次股东会所审议的议案内容以及该等议案所表述的相关事实或数据的 真实性、准确性或合法性发表意见。 本法律意见书仅供本次股东会之目的而使用，未经本所书面 ...

2、本次股东会没有涉及变更前次股东会决议。 一、会议召开和出席情况 1、现场会议召开时间：2025年12月5日（星期五）下午14：30 网络投票时间：2025年12月5日 证券代码：002693 证券简称：*ST双成 公告编号：2025-072 海南双成药业股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会没有出现否决议案的情形。 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年12 月5日9:15-9:25，9:30-11:30和13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的时间为2025年12月5日 9:15-15:00期间的任意时间。 2、会议召开地点：海南省海口市秀英区兴国路16号公司会议室 3、会议召开方式：现场投票结合网络投票方式 4、会议召集人：公司董事会 5、会议主持人：董事长王成栋 6、本次股东会会议的召集、召开和表决程序符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

Group 1 - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., will hold its third extraordinary general meeting of shareholders on December 5, 2025, as decided in the 24th meeting of the fifth board of directors [1][31] - The meeting will combine on-site voting and online voting, with specific time slots for each voting method [2][3] - Shareholders must register to attend the meeting between December 2 and December 3, 2025, and can delegate representatives to vote on their behalf [11][12] Group 2 - The board of directors has approved the termination of the 2025 restricted stock and stock option incentive plan due to the company's inability to complete the necessary registration and announcement within the stipulated 60 days [27][35] - The decision to terminate the incentive plan was made after considering the current operational situation and market conditions, ensuring it does not negatively impact the company's financial status or shareholder interests [36][37] - The company will not propose a new incentive plan for three months following the announcement of the termination [36]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has decided to terminate its stock incentive plan due to the inability to complete the necessary procedures within the stipulated 60 days following the shareholders' meeting approval, citing current operational challenges and market conditions as key factors [1] Group 1: Incentive Plan Details - The company was required to complete the grant registration and announcement within 60 days after the shareholders' meeting approved the incentive plan [1] - The failure to meet this deadline has led to the decision to terminate the incentive plan, as it was deemed unlikely to achieve the intended motivational effects [1] - The board of directors has also decided to terminate related documents, including the "2025 Restricted Stock and Stock Option Incentive Plan Implementation Assessment Management Measures" [1]

Group 1 - The company *ST Shuangcheng (SZ 002693) announced that its 24th meeting of the fifth board of directors was held on November 18, 2025, through a combination of on-site and remote voting [1] - The meeting reviewed the proposal for convening the third extraordinary general meeting of shareholders in 2025 [1] - For the first half of 2025, the company's revenue composition was 89.3% from industrial operations and 10.7% from service operations [1] Group 2 - As of the report date, the market capitalization of *ST Shuangcheng was 3.5 billion yuan [2]

证券代码：002693 证券简称：*ST双成 公告编号：2025-070 海南双成药业股份有限公司 关于终止实施 2025 年限制性股票与股票期权激励计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开 第五届董事会第二十四次会议，审议通过了《关于终止实施 2025 年限制性股票 与股票期权激励计划的议案》，由于公司未能在规定的时间内完成授予工作，经 公司董事会审慎研究，拟同意终止实施 2025 年限制性股票与股票期权激励计划 （以下简称"本激励计划"），同时与之配套的公司《2025 年限制性股票与股票 期权激励计划实施考核管理办法》等相关文件一并终止。该事项尚需提交公司股 东会审议，现将相关事项说明如下： 一、本激励计划已履行的审批程序和信息披露情况 1、2025 年 9 月 1 日，公司召开第五届董事会第二十一次会议，审议通过了 《关于<2025 年限制性股票与股票期权激励计划（草案）>及其摘要的议案》《关 于<2025 年限制性股票与股票期权激励计划实施考核管理办 ...

北京市中伦律师事务所 关于海南双成药业股份有限公司 终止实施 2025 年限制性股票与股票期权激励计划的 法律意见书 $$\underline{{{\ \ \ \ }}}\bullet\underline{{{\ \ \ }}}\mathbb{H}\mathbb{H}\mathbb{H}\mathbb{H}\mathbb{H}$$ 北京市中伦律师事务所 关于海南双成药业股份有限公司 终止实施 2025 年限制性股票与股票期权激励计划的 为出具本法律意见书，本所律师根据有关法律、法规、规范性文件的规定和 本所业务规则的要求，本着审慎性及重要性原则对本次终止有关的文件资料和事 实进行了核查和验证。 对本法律意见书，本所律师作出如下声明： 1. 本所律师在工作过程中，已得到双成药业的以下保证：即公司业已向本 所律师提供了本所律师认为制作法律意见书所必需的原始书面材料、副本材料和 口头证言，其所提供的文件和材料是真实、准确和完整的，且无隐瞒、虚假和重 大遗漏之处。 法律意见书 致：海南双成药业股份有限公司 根据海南双成药业股份有限公司（以下简称"双成药业"或"公司"）与北 京市中伦律师事务所（以下简称"本所"）签订的 ...